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70 Poster Session-Ibe given post ASCT; however, neuropathy is a significant common
toxicity that required patients to stop therapy. Longer follow-up is
needed to determine the duration of benefit of BLT-Dmaintenance.
With a median follow-up of 42.5 months, the majority of patients re-
main alive without evidence of disease progression.188
PERIPHERAL BLOOD CD34 COUNT CAN PREDICT SUCCESSFUL PROGEN-
ITOR CELL MOBILIZATION IN POOR MOBILIZIERS TREATED WITH
PLERIXAFOR AND G-CSF
Micallef, I.N.1, Maurer, M.2, Ansell, S.M.1, Buadi, F.1, Dispenzieri, A.1,
Gastineau, D.A.1, Gertz, M.A.1, Hayman, S.R.1, Hogan, W.J.1,
Inwards, D.J.1, Johnston, P.B.1, Kumar, S.1, Lacy, M.Q.1, Litzow, M.R.1,
Porrata, L.F.1, Winters, J.L.3, Marzolf, M.1, Shaw, T.1, Calandra, G.4
1Mayo Clinic, Rochester, MN; 2Mayo Clinic, Rochester, MN; 3Mayo Clinic,
Rochester, MN; 4Genzyme Transplant, Cambridge, MA
Background:The failure rate for CD341 cell mobilization varies
from 5% in MM to 30% in NHL and HD.
Methods:We report the results of a single center experience with
plerixafor1G-CSF as re-mobilization in patients whom a prior mo-
bilization has failed. Mobilization failure was defined as inability to
collect 2  106 CD341 cells/kg or inability to achieve a peripheral
blood CD341 cells/ml of $10 and not apheresed. Re-mobilization
consisted of G-CSF at 10mcg/kg/day sq on days 1–4 plus plerixafor
240 mcg/kg/day sq on the evening of day 4. Both drugs were contin-
ued daily until a goal of 5  106 CD341 cells/kg was reached or
a maximum of 7 aphereses. Apheresis began on day 5 regardless of
the peripheral blood (pb) CD 341 cells/ml. PB CD341 was corre-
lated to CD341 harvested. In addition, we sought to determine if
there was a pb CD341 count pre or post plerixafor that would pre-
dict for a successful harvest of either 2 or 5 106 CD341 cells/kg.
Results: Baseline demographics were as follows: 54 patients, 25
females: 29 males; 29 NHL, 15 MM, 6 HD and 4 AL amyloidosis.
Median age was 64 years (range 30–76). Prior mobilization was
predominantly G-CSF alone. Median time from prior mobilization
to re-mobilization was 0.7 months (range 0.4–33 months). The me-
dian pb CD341 cells/ml prior to plerixafor was 4.5 (range 0–25)
and 12 hours post plerixaforwas 11.5 (range 0–50).Themedian num-
ber harvestedwas 4.61106CD341 cells/kg (range0.08–9.37). 41%
of patients successfully collected$ 5106 CD341 cells/kg and 74%
collected $ 2 106 CD341 cells/kg. PB CD341 correlated with
CD341 harvested on a daily basis (p \0.0001). PB CD341 pre
and post plerixaforwas able to predict success of collection (see table).
% success % successPB CD341 cells/ml
$2  106 CD341
cells/kg
$5  106
CD341 cells/kgPre-Plerixafor
\5 56% 25%
5–10 100% 64%Post Plerixafor
\5 15% 8%
5–10 83% 8%
.10 97% 69%Conclusion: The combination of plerixafor and G-CSF effec-
tively mobilizes CD341 cells in the majority of pts, in whom a prior
mobilization has failed. PB CD341 remains an important predictor
of CD341 harvested. PB CD341 pre-plerixafor of $5 cells/ ml is
associated with a 100% success rate.189
USE OF SECOND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANS-
PLANTS FOR THE TREATMENT OF MULTIPLE MYELOMA
Harris, P.J., Ririe, D.W. San Antonio Military Medical Center South,
Lackland AFB, TX
Introduction: In patientswith newly diagnosedmultiplemyeloma
who are candidates for autologous stem cell transplant (ASCT), it is
often recommended to proceed straight to ASCT after a response
to initial induction therapy as a way of prolonging progression freesurvival compared to chemotherapy alone. Second (tandem) ASCTs
have been routinely performed in patients with less than a very good
partial response to first transplant, since data has shown improved
survival in this subset of patients. We were interested in reviewing
the number of patients who had received single or tandem ASCTs
formultiplemyeloma, and to evaluate factors influencing thedecision
of whether or not to proceed to a second ASCT.
Methods: This is a single institution retrospective review of pa-
tients who have received an ASCT for multiple myeloma from 1
Jan 2000 until 15 April 2008 at San AntonioMilitaryMedical Center
South in San Antonio, TX. Data was collected regarding patient age,
stage, performance status, cytogenetics, lactate dehydrogenase, beta
-2- microglobulin and albumin levels at diagnosis, treatment given,
number of cells harvested and number and type of transplants
received as well as response to each transplant.
Results: Seventeen of 81 patients (21%)who received oneASCT for
the diagnosis of multiple myeloma went on to receive a second ASCT.
Discussion: Seventy-nine percent of patients at our institution
during the specified times did not receive a tandem ASCT for mul-
tiple myeloma. Patient and disease factors which may have influ-
enced the decision of whether to proceed to a second ASCT are
discussed. Since many patients do not receive the second transplant,
and with the cost of and space required to store unused harvested
cells as well as the time and effort required of patients to collect
enough cells for two transplants, this data may help reduce initial
over collection of hematopoietic stem cells.190
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Many tumors harbor chronic and intermittent hypoxic cellular
niches giving a survival advantage to malignant cells including cancer
stem cells. To achieve a successful immunotherapeutic response, T
cellsmust overcome physiological challenges specific to the tumormi-
croenvironment such as hypoxia. To exploit the hypoxic tumormicro-
environment, we introduce a new approach that exploits hypoxia as
a condition for T-cell activation. In addition, this approach may be
used to limit off-target effects to normal cells expressing antigen under
normoxia. We demonstrate that a chimeric antigen receptor (CAR),
which is specific forCD19, expressed onmalignant and normal B cells,
can be conditionally expressed in a strictly oxygen-sensitive manner.
Using the Sleeping Beauty transposon/transposase system, we can
achieve stable, persistent CAR transgene expression from DNA plas-
mids without the expense and complexity of retroviral production.
Cell surface expressionof ourCAR is high at 1%O2 andnot detectable
at 20%O2. This oxygen-sensitive CAR is designed to deactivate when
Tcells circulate out of hypoxic tumormicroenvironments tominimize
deleterious off-target effects in vivo. When supplemented with one or
more survival factors and/or homing receptors, this approach to CAR
expression has the advantage of transforming hypoxia from an adverse
factor to a T-cell triggering mechanism. This is expected to be of
broad interest as investigators implement T-cell immunotherapy to
eliminate tumors from the hypoxic niche aswell as develop approaches
that limit T-cell targeting within desired microenvironments thereby
decreasing the possibility of inadvertent targeting of normal tissues.191
CONTINUED M PROTEIN RESPONSES BEYOND DAY 100 AFTER AUTOLO-
GOUS TRANSPLANTATION FOR MYELOMA: IMPLICATIONS FOR POST
TRANSPLANT STRATEGIES
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Background: Patients undergoing autologous stem cell trans-
plantation (SCT) for myeloma usually undergo disease evaluation
approximately 100 days after the SCT. Decisions regarding post
